Viridian Therapeutics, Inc.
VRDN- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001590750
In the last 90 days, Viridian Therapeutics, Inc. insiders filed 0 open-market purchases and 1 sale; 214 institutions reported holding it in 13F filings for Q2 2026, worth $2.50B in total; no superinvestor holds it.
Open-market trades, last 90 days
Open-market purchases (P) and sales (S) by Viridian Therapeutics, Inc. insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.
- Open-market buys
- 0 filings
- Open-market sells
- 1 filing
- 1 insider, $348.2K in total
- Insiders trading
- 1
- Net value
- −$348.2K
- Purchases minus sales
Insider roster
Directors, officers and 10% owners who have filed a Form 4 for Viridian Therapeutics, Inc., current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.
| Name | Title | Last reported holding | Last filing | Filings, past year |
|---|---|---|---|---|
| Tousignant Jennifer | Chief Legal Officer | 0 | Aug 20, 2026 | 5 |
| Tripuraneni Radhika | Chief Medical Officer | 40,000 | Aug 18, 2026 | 2 |
| Cain Christopher W. | Director | – | Jul 2, 2026 | 1 |
| Ajer Jeffrey Robert | Director | – | Jul 2, 2026 | 1 |
| Moses Jennifer K. | Director | – | Jul 2, 2026 | 1 |
| Gheuens Sarah | Director | – | Jul 2, 2026 | 1 |
| Kiselak Tomas | Director | – | Jul 2, 2026 | 1 |
| Morris Arlene | Director | – | Jul 2, 2026 | 1 |
| Fairmount Healthcare Fund II L.P. | Director, 10% Owner | 5,090,928Indirect | May 13, 2026 | 2 |
| Fairmount Funds Management LLC | Director, 10% Owner | 5,090,928Indirect | May 13, 2026 | 2 |
| Fairmount Healthcare Fund II GP LLC | Director, 10% Owner | 5,090,928Indirect | May 13, 2026 | 2 |
| Beetham Thomas W. | Chief Operating Officer | 13,361 | Mar 9, 2026 | 1 |
| Mahoney Stephen F. | President and CEO | 33,349 | Mar 9, 2026 | 1 |
| Harmon Seth | Chief Financial Officer | 7,850 | Mar 9, 2026 | 3 |
| Harwin Peter Evan | Director | – | Jun 28, 2024 | 0 |
| Fairmount Healthcare Fund L.P. | Director | 1,845,813Indirect | Apr 1, 2024 | 0 |
| Fairmount Healthcare Fund GP LLC | Director | 1,845,813Indirect | Apr 1, 2024 | 0 |
| Ciulla Thomas | Chief Medical Officer | – | Feb 7, 2024 | 0 |
| Meisner Lara | Chief Legal Officer | 29,971 | Jun 20, 2023 | 0 |
| Myers Scott Dunseth | Chief Executive Officer | 259,500 | Apr 12, 2023 | 0 |
| Katz Barrett | Chief Medical Officer | 0 | Feb 10, 2023 | 0 |
| Humer Kristian | CFO and CBO | – | Feb 10, 2023 | 0 |
| Melvin Carrie | COO | – | Feb 10, 2023 | 0 |
| Violin Jonathan | Chief Executive Officer | 480,905 | Feb 7, 2023 | 0 |
| Frazier Life Sciences Public Fund, L.P. | 10% Owner | 1,505,200 | Sep 28, 2021 | 0 |
| FHMLSP, L.L.C. | 10% Owner | 1,505,200 | Sep 28, 2021 | 0 |
| FHMLSP, L.P. | 10% Owner | 1,505,200 | Sep 28, 2021 | 0 |
Insider trades
Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Aug 20, 2026 (view filing)8:05 PM ET | Aug 19 | 1 day | Tousignant JenniferChief Legal Officer | SSale | −14.2K | $24.50 | −$348.2K | −100.0%0 after | 2 lots |
| May 13, 2026 (view filing)4:31 PM ET | May 11 | 2 days | Fairmount Healthcare Fund II L.P. and 2 othersDirector, 10% Owner | PPurchase | +1.18M | $17.00 | +$20.0M | +30.1%5.09M after | |
| Jan 2, 2026 (view filing) | Dec 31, 2025 | 2 days | Tousignant JenniferChief Legal Officer | SSale | −2.27K | $31.16 | −$70.8K | −100.0%0 after | |
| Oct 27, 2025 (view filing)4:30 PM ET | Oct 23 | 4 days | Fairmount Healthcare Fund II L.P. and 2 othersDirector, 10% Owner | PPurchase | +454.5K | $22.00 | +$10.0M | +13.1%3.91M after | |
| Sep 30, 2024 (view filing) | Sep 27 | 3 days | Beetham Thomas W.Chief Operating Officer | PPurchase | +5.00K | $23.41 | +$117.0K | +500.0%6.00K after | |
| Sep 30, 2024 (view filing) | Sep 27 | 3 days | Mahoney Stephen F.President and CEO | PPurchase | +21.4K | $23.33 | +$499.3K | New position21.4K after | |
| Sep 17, 2024 (view filing)9:00 PM ET | Sep 13 | 4 days | Fairmount Healthcare Fund II L.P. and 2 othersDirector, 10% Owner | PPurchase | +1.60M | $18.75 | +$30.0M | +86.7%3.45M after | |
| Jan 24, 2024 (view filing)6:44 PM ET | Jan 22 | 2 days | Fairmount Healthcare Fund L.P. and 4 othersDirector, Other: See Remarks | PPurchase | +476.2K | $21.00 | +$10.0M | +34.9%1.84M after | |
| Jun 20, 2023 (view filing) | Jun 15-16 | 5 days | Meisner LaraChief Legal Officer | SSale | −2.30K | $28.02 | −$64.3K | −7.1%30.0K after | 2 lots |
| Jun 6, 2023 (view filing) | Jun 2-6 | 4 days | Meisner LaraChief Legal Officer | SSale | −7.50K | $24.82 | −$186.1K | −20.0%30.0K after | 3 lots10b5-1 |
| Apr 12, 2023 (view filing) | Apr 12 | Same day | Myers Scott DunsethChief Executive Officer | PPurchase | +4.00K | $25.37 | +$101.5K | +1.6%259.5K after | |
| Mar 13, 2023 (view filing) | Mar 13 | Same day | Myers Scott DunsethChief Executive Officer | PPurchase | +5.50K | $29.15 | +$160.3K | +2.2%255.5K after | |
| Mar 10, 2023 (view filing) | Mar 9 | 1 day | Meisner LaraGeneral Counsel and Secretary | SSale | −30.0K | $29.07 | −$871.3K | −100.0%0 after | |
| Feb 7, 2023 (view filing)6:35 PM ET | Feb 2 | 5 days | Violin JonathanChief Executive Officer | SSale | −50.0K | $36.80 | −$1.84M | −9.4%480.9K after | Amended |
| Jan 25, 2023 (view filing) | Jan 23 | 2 days | Meisner LaraGeneral Counsel and Secretary | SSale | −6.84K | $35.66 | −$244.0K | −100.0%0 after | |
| Jan 18, 2023 (view filing) | Jan 13-17 | 5 days | Katz BarrettChief Medical Officer | SSale | −29.0K | $37.18 | −$1.08M | −100.0%0 after | 2 lots |
| Jan 11, 2023 (view filing) | Jan 9-10 | 2 days | Katz BarrettChief Medical Officer | SSale | −60.0K | $34.82 | −$2.09M | −100.0%0 after | 2 lots |
| Dec 22, 2022 (view filing) | Dec 20-21 | 2 days | Meisner LaraGeneral Counsel and Secretary | SSale | −16.9K | $29.15 | −$493.4K | −100.0%0 after | 2 lots |
| Dec 19, 2022 (view filing) | Dec 15-16 | 4 days | Meisner LaraGeneral Counsel and Secretary | SSale | −1.60K | $28.37 | −$45.3K | −100.0%0 after | 2 lots |
| Dec 14, 2022 (view filing) | Dec 12-14 | 2 days | Meisner LaraGeneral Counsel and Secretary | SSale | −16.3K | $28.12 | −$457.1K | −100.0%0 after | 2 lots |
| Nov 16, 2022 (view filing) | Nov 15 | 1 day | Meisner LaraGeneral Counsel and Secretary | SSale | −8.13K | $22.05 | −$179.2K | −100.0%0 after | |
| Aug 19, 2022 (view filing)4:32 PM ET | Aug 17 | 2 days | Fairmount Healthcare Fund L.P. and 4 othersDirector, 10% Owner | PPurchase | +425.5K | $23.50 | +$10.0M | +45.4%1.36M after | |
| Jun 2, 2022 (view filing) | Jun 1 | 1 day | Violin JonathanChief Executive Officer | SSale | −30.0K | $12.20 | −$366.0K | −5.9%480.9K after | |
| May 4, 2022 (view filing) | May 2 | 2 days | Violin JonathanChief Executive Officer | SSale | −30.0K | $13.04 | −$391.2K | −5.5%510.9K after | |
| Apr 5, 2022 (view filing) | Apr 1-4 | 4 days | Violin JonathanChief Executive Officer | SSale | −30.0K | $18.92 | −$567.6K | −5.3%540.9K after | 2 lots |
| Mar 3, 2022 (view filing) | Mar 1-2 | 2 days | Violin JonathanChief Executive Officer | SSale | −30.0K | $17.65 | −$529.5K | −5.0%570.9K after | 2 lots |
| Feb 3, 2022 (view filing) | Feb 1-3 | 2 days | Violin JonathanChief Executive Officer | SSale | −30.0K | $19.09 | −$572.8K | −4.8%600.9K after | 3 lots |
| Sep 28, 2021 (view filing)7:46 PM ET | Sep 23 | 5 daysLate | Frazier Life Sciences Public Fund, L.P. and 2 others10% Owner | PPurchase | +200.0K | $11.00 | +$2.20M | +15.3%1.51M after | |
| Sep 23, 2021 (view filing)9:30 AM ET | Sep 21 | 2 days | Fairmount Healthcare Fund L.P. and 4 othersDirector, Other: See Remarks | PPurchase | +909.0K | $11.00 | +$10.0M | +3,109.5%938.2K after |